首页 | 本学科首页   官方微博 | 高级检索  
     检索      


The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Authors:Barretina Jordi  Caponigro Giordano  Stransky Nicolas  Venkatesan Kavitha  Margolin Adam A  Kim Sungjoon  Wilson Christopher J  Lehár Joseph  Kryukov Gregory V  Sonkin Dmitriy  Reddy Anupama  Liu Manway  Murray Lauren  Berger Michael F  Monahan John E  Morais Paula  Meltzer Jodi  Korejwa Adam  Jané-Valbuena Judit  Mapa Felipa A  Thibault Joseph  Bric-Furlong Eva  Raman Pichai  Shipway Aaron  Engels Ingo H  Cheng Jill  Yu Guoying K  Yu Jianjun  Aspesi Peter  de Silva Melanie  Jagtap Kalpana  Jones Michael D  Wang Li  Hatton Charles  Palescandolo Emanuele  Gupta Supriya  Mahan Scott  Sougnez Carrie  Onofrio Robert C  Liefeld Ted
Institution:The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA.
Abstract:The systematic translation of cancer genomic data into knowledge of tumour biology and therapeutic possibilities remains challenging. Such efforts should be greatly aided by robust preclinical model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacological annotation is available. Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy number and massively parallel sequencing data from 947 human cancer cell lines. When coupled with pharmacological profiles for 24 anticancer drugs across 479 of the cell lines, this collection allowed identification of genetic, lineage, and gene-expression-based predictors of drug sensitivity. In addition to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was associated with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors. Together, our results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents. The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of 'personalized' therapeutic regimens.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号